GW Pharma (GWPH) PT Raised to $182 at Cantor Fitzgerald Following Successful Second LGS Trial

September 26, 2016 9:48 AM EDT
Get Alerts GWPH Hot Sheet
Price: $112.32 +2.78%

Rating Summary:
    9 Buy, 0 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade GWPH Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Cantor Fitzgerald analyst Elemer Piros raised his price target on Buy-rated GW Pharma (NASDAQ: GWPH) to $182.00 (from $165.00) after the company reported a second successful pivotal trial in Lennox-Gastaut syndromes (LGS).

Piros commented, "The second LGS trial was in most respects a carbon copy of the results obtained in the first one. The drug worked in a highly refractory patient population on top of additional drugs, beating placebo by a wide margin. At study entry, patients have already failed seven other drugs and experienced a drop seizure frequency of 85/month. During the trial patients (n=225) were taking, on average, three additional drugs plus two doses of Epidiolex or placebo. Fourteen weeks after starting treatment, seizure frequency was reduced by 17% in the placebo group vs. by 37% (p=0.0016) in the 10mg/kg arm and by 42% (p=0.0047) for those who took the 20mg/kg dose. As a reminder, the seizure reduction rate was 44% (20mg/kg) in the previous Phase 3 trial."

For an analyst ratings summary and ratings history on GW Pharma click here. For more ratings news on GW Pharma click here.

Shares of GW Pharma closed at $107.56 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst PT Change, FDA

Related Entities

Cantor Fitzgerald

Add Your Comment